Prospects of combined antihypertensive-psychocorrective therapy in women with arterial hypertension and anxiety-depressive disorders: clinical randomized placebo uncontrolled trial

Background. Anxiety-depressive disorders (ADD) afflict almost half of patients with arterial hypertension (AH). AH aggravation by psychoemotional disorders causes a more severe illness and rapid target organ injury, particularly, the increased arterial stiffness and central aortic pressure (CAP). However, the prospects of combined antihypertensive-antidepressant treatments in AH-ADD patients remain largely unexplored.

Objectives. The effect assessment in combined antihypertensive-psychocorrective therapy on circadian blood pressure (BP), vascular stiffness and CAP, anxiety and depression in women with AH and ADD.

Methods. The study enrolled 60 AH-ADD women randomised between two cohorts. Cohort 1 received a fixed combination of valsartan and hydrochlorothiazide, bisoprolol and sertraline antidepressant; cohort 2 only had same combined AH therapy. Past 24 weeks of trial, all patients had a general clinical examination and daily blood pressure monitoring (DBPM) with BpLab Vasotens (Petr Telegin Ltd., Russia) and control of daily BP, CAP and vascular stiffness. The psychometric HADS and CES-D scales were used along with psychiatric counselling.

Results. Past four weeks of treatment, the target blood pressure (TBP) was revealed in 60 and 36.7% patients, and in 90 and 66.6% — past eight weeks in cohorts 1 and 2, respectively. Cohort 1 vs. 2 required a lower valsartan dose to attain TBP. Past six months, both cohorts showed improved main DBPM values reflecting vascular stiffness and CAP. However, a statistical decrease in nocturnal central and peripheral BP, as well as improved BP variability and vascular stiffness were registered at antidepressant use. A normalised daily BP profile was significantly more frequent in cohort 1. In addition, sertraline had a significant ADD-reductive impact.

Conclusion. An antidepressant-combined conventional AH therapy in AH-ADD women facilitated a faster TBP achievement at lower AH agent doses and the significantly improved DBPM (nocturnal specifically), arterial stiffness and CAP values. A sertraline treatment improved the psychoemotional patient state.

1. Piepoli M.F., Hoes A.W., Agewall S., Albus C., Brotons C., Catapano A.L., Cooney M.T., Cor-ra U., Cosyns B., Deaton C., Graham I., Hall M.S., Hobbs F.D.R., Lochen M.L, Lollgen H., Marques-Vidal P., Perk J., Prescott E., Redon J., Richter D.J., Sattar N., Smulders Y, Tiberi M., van der Worp H.B., van Dis I., Verschuren W.M.M., Binno S.; ESC Scientific Document Group. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur. Heart J. 2016; 37(29): 23152381. DOI: 10.1093/eurheartj/ehw106

2. Pogosova N.V., Boitsov S.A., Oganov R.G., Kostyuk G.P., Sokolova O.Yu., Yufereva Yu.M., Kursa-kov A.A., Ausheva A.K., Vygodin V.A., Karpova A.V., Arutyunov A.A., Isakova S.S. Psychosocial Risk Factors in Ambulatory Patients With Arterial Hypertension and Ischemic Heart Disease of 30 Cities in Russia: Data from the КОМЕТА (COMET) Study. Kardiologi-ya. 2018; 58(11): 5-16 (In Russ., English abstract). DOI: 10.18087/cardio.2018.11.10193

3. Santos-Veloso M.A.O., Melo M.I.S.L., Cavalcanti R.A.N., Bezerra L.S., Chaves-Markman A.V., Lima S.G. Prevalence of depression and anxiety and their association with cardiovascular risk factors in Northeast Brasil primary care patients. Rev. Assoc. Med. Bras. (1992). 2019; 65(6): 801-809. DOI: 10.1590/1806-9282.65.6.801

4. Otten D., Tibubos A.N., Schomerus G., Brahler E., Binder H., Kruse J., Ladwig K.H., Wild PS., Gra-be H.J., Beutel M.E. Similarities and differences of mental health in women and men: a systematic review of findings in three large german cohorts. Front. Public. Health. 2021; 9: 553071. DOI: 10.3389/fpubh.2021.553071

5. Zhao S., Wang X., Chen Z., Zhou H., Han Y, Tang H., Yan R., Yao Z., Lu Q. Sex differences in the association between symptom profiles and cognitive functioning in patients with depressive disorder. J. Affect. Disord. 2021; 287: 1-7. DOI: 10.1016/j.jad.2021.03.020

6. Cui F., Zhang N., Yi J., Liang Y, Liu Q. Influence of hostility on 24-hour diastolic blood pressure load in hypertension patients with depressive disorders. Med. Sci. Monit. 2021; 27: e929710. DOI: 10.12659/MSM.929710

7. van Sloten T.T., Mitchell G.F., Sigurdsson S., van Bu-chem M.A., Jonsson PV., Garcia M.E., Harris T.B., Henry R.M., Levey A.S., Stehouwer C.D., Gudnason V., Launer L.J. Associations between arterial stiffness, depressive symptoms and cerebral small vessel disease: cross-sectional findings from the AG-ES-Reykjavik Study. J. Psychiatry. Neurosci. 2016; 41(3): 162-168. DOI: 10.1503/jpn.140334

8. Almeida O.P, Ford A.H., Hankey G.J., Golledge J., Yeap B.B., Flicker L. Depression, antidepressants and the risk of cardiovascular events and death in older men. Maturitas. 2019; 128: 4-9. DOI: 10.1016/j.maturitas.2019.06.009

9. Bulas J., Potocarova M., Murfn J., Kozlfkova K., Luha J., Caprnda M. Central Systolic Hypertension in Patients with Well-Controlled Hypertension. Biomed. Res. Int. 2017; 2017: 8158974. DOI: 10.1155/2017/8158974

10. Kokras N., Papadopoulou E., Georgiopoulos G., Dal-la C., Petropoulos I., Kontogiannis C., Laina A., Bam-patsias D., Stellos K., Kouzoupis A.V., Stamatelopoulos K. The effect of treatment response on endothelial function and arterial stiffness in depression. A prospective study. J. Affect. Disord. 2019; 252: 190-200. DOI: 10.1016/j.jad.2019.04.024

11. Kobalava Z.D., Konradi A.O., Nedogoda S.V., Shlyakhto E.V., Arutyunov G.P, Baranova E.I., Bar-barash O.L., Boitsov S.A., Vavilova T.V., Villevalde S.V., Galyavich A.S., Glezer M.G., Grineva E.N., Grinstein Yu.I., Drapkina O.M., Zhernakova Yu.V., Zvartau N.E., Kislyak O.A., Koziolova N.A., Kosmache-va E.D., Kotovskaya Yu.V., Libis R.A., Lopatin Yu.M., Nebiridze D.V., Nedoshivin A.O., Ostroumova O.D., Oschepkova E.V., Ratova L.G., Skibitsky V.V., Tkacheva O.N., Chazova I.E., Chesnikova A.I., Chumakova G.A., Shalnova S.A., Shestakova M.V., Yakushin S.S., Yanishevsky S.N. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020; 25(3): 3786 (In Russ.). DOI: 10.15829/1560-4071-2020-3-3786

12. Williams B., Mancia G., Spiering W., Agabiti Rosei E., Azizi M., Burnier M., Clement D., Coca A., De Simone G., Dominiczak A., Kahan T., Mahfoud F, Redon J., Ruilope L., Zanchetti A., Kerins M., Kjeldsen S., Kreutz R., Laurent S., Lip G.Y.H., McManus R., Narkiewicz K., Ruschitzka F., Schmieder R., Shlyakhto E., Tsioufis K., Aboyans V., Desormais I. 2018 Practice Guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. Blood Press. 2018; 27(6): 314-340. DOI: 10.1080/08037051.2018.1527177

13. Kobalava Z.D., Konradi A.O., Nedogoda S.V., Arutyu-nov G.P, Baranova E.I., Barbarash O.L., Villeval-de S.V., Galyavich A.S., Glezer M.G., Drapkina O.M., Kotovskaya Yu.V., Libis R.A., Lopatin Yu.M., Ne-doshivin A.O., Ostroumova O.D., Ratova L.G., Tkacheva O.N., Chazova I.E., Chesnikova A.I., Chumakova G.A. Russian Society of Cardiology position paper on 2018 Guidelines of the European Society of Cardiology / European Society of Arterial Hypertension for the management of arterial hypertension. Russian Journal of Cardiology. 2018; 12: 131-142 (In Russ., English abstract). DOI: 10.15829/1560-4071-2018-12-131-142

14. Kozlov A.I., Kozlova M.A. Cortisol as a marker of stress. Human Physiology. 2014; 40(2): 224-236. DOI: 10.1134/S0362119714020091

15. Chazova I.E., Zhernakova Yu.V. on behalf of the experts. Clinical guidelines. Diagnosis and treatment of arterial hypertension. Systemic Hypertension. 2019; 16(1): 6-31 (In Russ.). DOI: 10.26442/2075082X.2019.1.190179

16. Mohite S., Sanches M., Teixeira A.L. Exploring the evidence implicating the renin-angiotensin system (ras) in the physiopathology of mood disorders. Protein. Pept. Lett. 2020; 27(6): 449-455. DOI: 10.2174/0929866527666191223144000

17. Bahramali E., Firouzabadi N., Yavarian I., Shayesteh M.R., Erfani N., Shoushtari A.A., Asadpour R. Influence of ACE gene on differential response to sertraline versus fluoxetine in patients with major depression: a randomized controlled trial. Eur. J. Clin. Pharmacol. 2016; 72(9): 1059-1064. DOI: 10.1007/s00228-016-2079-0

18. Fugger G., Dold M., Bartova L., Kautzky A., Souery D., Mendlewicz J., Serretti A., Zohar J., Montgomery S., Frey R., Kasper S. Comorbid hypertension in patients with major depressive disorder — Results from a European multicenter study. Eur. Neuropsychopharma-col. 2019; 29(6): 777-785. DOI: 10.1016/j.euroneu-ro.2019.03.005

19. Vaclavik J., Krenkova A., Kocianova E., Vaclavik T., Kamasova M. Effect of sertraline in paroxysmal hypertension. Biomed. Pap. Med. Fac. Univ. Palacky Olo-mouc. Czech. Repub. 2018; 162(2): 116-120. DOI: 10.5507/bp.2017.039

20. Singla S., Jhamb S., Singh K.D., Kumar A. Depression affects autonomic system of the body? Yes, it does! J. Educ. Health. Promot. 2020; 9: 217. DOI: 10.4103/jehp.jehp_627_19

21. Casagrande M., Favieri F., Langher V., Guarino A., Di Pace E., Germano G., Forte G. The Night Side of Blood Pressure: Nocturnal Blood Pressure Dipping and Emotional (dys)Regulation. Int. J. Environ. Res. Public. Health. 2020; 17(23): 8892. DOI: 10.3390/ijerph17238892

22. Peng L., Bi S., Liu X., Long T., Zhao Y., Li F., Yang T., Zhang C. Association between depressive symptoms and arterial stiffness: a cross-sectional study in the general Chinese population. BMJ Open. 2020; 10(2): e033408. DOI: 10.1136/bmjopen-2019-033408

23. Won E., Kim Y.K. Stress, the autonomic nervous system, and the immune-kynurenine pathway in the etiology of depression. Curr. Neuropharmacol. 2016; 14(7): 665-673. DOI: 10.2174/1570159x14666151208113006

24. Beurel E., Toups M., Nemeroff C.B. The bidirectional relationship of depression and inflammation: double trouble. Neuron. 2020; 107(2):234-256. DOI: 10.1016/j.neuron.2020.06.002

25. Kohler C.A., Freitas T.H., Maes M., de Andrade N.Q., Liu C.S., Fernandes B.S., Stubbs B., Solmi M., Veronese N., Herrmann N., Raison C.L., Miller B.J., Lanctot K.L., Carvalho A.F. Peripheral cytokine and chemokine alterations in depression: a meta-analysis of 82 studies. Acta. Psychiatr. Scand. 2017; 135(5): 373-387. DOI: 10.1111/acps.12698

26. Wang L., Wang R., Liu L., Qiao D., Baldwin D.S., Hou R. Effects of SSRIs on peripheral inflammatory markers in patients with major depressive disorder: A systematic review and meta-analysis. Brain. Behav. Immun. 2019; 79: 24-38. DOI: 10.1016/j.bbi.2019.02.021

27. Zapolski T, Kaminska A., Kocki T, Wysokinski A., Ur-banska E.M. Aortic stiffness-Is kynurenic acid a novel marker? Cross-sectional study in patients with persistent atrial fibrillation. PLoS One. 2020; 15(7): e0236413. DOI: 10.1371/journal.pone.0236413

28. Kohler C.A., Freitas T.H., Stubbs B., Maes M., Sol-mi M., Veronese N., de Andrade N.Q., Morris G., Fernandes B.S., Brunoni A.R., Herrmann N., Raison C.L., Miller B.J., Lanctot K.L., Carvalho A.F. Peripheral alterations in cytokine and chemokine levels after antidepressant drug treatment for major depressive disorder: systematic review and meta-analysis. Mol. Neurobiol. 2018; 55(5): 4195-4206. DOI: 10.1007/s12035-017-0632-1

29. Lopez-Vilchez I., Diaz-Ricart M., Navarro V., Torramade S., Zamorano-Leon J., Lopez-Farre A., Galan A.M., Gasto C., Escolar G. Endothelial damage in major depression patients is modulated by SSRI treatment, as demonstrated by circulating biomarkers and an in vitro cell model. Transl. Psychiatry. 2016; 6(9): e886. DOI: 10.1038/tp.2016.156

30. Hoirisch-Clapauch S., Nardi A.E. Antidepressants: bleeding or thrombosis? Thromb. Res. 2019; 181 (Suppl 1): S23-S28. DOI: 10.1016/S0049-3848(19)30362-7